Biotech | June 01, 2022
Novavax initiates phase 3 trial of its COVID-19 omicron booster
Trial will assess safety and antibody responses of NVX-CoV2515 to the Omicron variant of COVID-19
Trial will assess safety and antibody responses of NVX-CoV2515 to the Omicron variant of COVID-19
The Innovation Explorer database of GlobalData’s Disruptor Intelligence Center highlights how blockchain ensures the authenticity of products thereby, improves trust, traceability, and transparency across key sectors
RSV is the most common viral cause of respiratory tract infections in newborns, young children, older adults, or the immunocompromised
The study was conducted in equal laboratory conditions in the Spallanzani Institute in Italy on comparable sera samples from individuals vaccinated with Sputnik V and Pfizer with a similar level of IgG antibodies and virus-neutralizing activity (VNA) against Wuhan variant.
Pfizer calls upon global health leaders and organizations to join the Accord, bringing their expertise and resources to close the health equity gap
Includes thermostabilized Ebola vaccines
Approval follows CHMP recommendation for use in patients previously vaccinated with Vaxzevria or an EU-approved mRNA Covid-19 vaccine
The company will invest approximately €440 million to increase membrane manufacturing capacity in Carrigtwohill and to build a new manufacturing facility at Blarney Business Park, both in Cork, Ireland
The vaccine was found to have 64% efficacy against symptomatic disease and 92% against severe Covid-19
The latest certification endorses product for cold chain monitoring across 194 WHO member countries
Subscribe To Our Newsletter & Stay Updated
